Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2000

View Archived Issues

5-HT1A receptor agonist MKC-242 has antiaggressive activity in isolated mice

Ro-60-0175 exerts differential effects in combination with antidepressants in mouse model

Photofrin approved in Sweden, Ireland and Italy

Maxim submits NDA for Maxamine

Innohep approved by FDA for DVT

Arsenic trioxide receives third orphan drug designation from FDA

Nucleotides in development at Inspire for various clinical indications

Inhibitors of fungal chitin synthase a focus of research at Roche

SM-20550 provides protection against I/R-induced skeletal muscle injury

Role of vasopressin and vasopressin antagonists in heart failure reviewed at recent congress

Centaur completes enrollment in phase IIa Parkinson's disease trial

Added benefit of ET blockade and angiotensin receptor antagonism in CHF

M-Vax now available in Australia for melanoma therapy

Emivirine may be useful for preventing perinatal transmission of HIV, as reported at AIDS conference

Micrologix Biotech advances additional products into clinical trials

HIV-1 RT dimer destabilization as a target for new antiviral agents

Potent anti-HIV activity described for human lysozyme fragments at AIDS conference

Genzyme General files MAA for approval of Fabrazyme in Europe

EMEA accepts MAA for Replagal as treatment of Fabry disease

Design and characterization of low-affinity, short-acting A2A AdoR agonists

ZymoGenetics isolates new PDGF-alpha receptor-binding polypeptide

Triazolo CCR3 receptor antagonists claimed by Toray for Rx of allergic diseases, etc.

Banyu presents new heterocyclic ORL1 receptor antagonists, their preparation and use

Indena's new colchicine derivatives active against multidrug-resistant cancer cells

K-5993: a new peptide IL-4 antagonist

Novel series of antioxidants emerges from R&D at ADIR

Novel COMT inhibitors for Parkinson's disease under study at Portela

Antisense modulators of EGR-1 expression patented by Isis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...